Compare IKT & USAU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | USAU |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.5M | 214.2M |
| IPO Year | 2020 | 2020 |
| Metric | IKT | USAU |
|---|---|---|
| Price | $2.46 | $15.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $5.00 | ★ $22.83 |
| AVG Volume (30 Days) | ★ 960.3K | 231.7K |
| Earning Date | 03-26-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.76 | 36.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $17,402,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $10.32 |
| 52 Week High | $2.53 | $23.72 |
| Indicator | IKT | USAU |
|---|---|---|
| Relative Strength Index (RSI) | 68.09 | 55.47 |
| Support Level | $1.63 | $14.15 |
| Resistance Level | $2.53 | $16.50 |
| Average True Range (ATR) | 0.14 | 0.72 |
| MACD | 0.01 | 0.26 |
| Stochastic Oscillator | 92.68 | 78.93 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.